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Background
Peanut allergy is a potentially life threatening condition,
which usually persists lifelong. Allergen avoidance is
challenging as reactions often occur to traces of peanut
in processed foods.
Methods
We present the case of a girl, who was diagnosed with
peanut allergy at age 8 after she developed abdominal
pain, urticaria and angioedema following a meal of corn-
flakes with peanut chips. No food challenge was per-
formed at that time, and she was advised to avoid peanuts.
Despite avoiding foods visibly containing peanut, she
repeatedly experienced urticaria, burning of the tongue,
nausea, and vomiting after consumption of different
chocolates and ice creams. At age 13, she experienced a
first episode of dyspnea and wheezing after eating a cake.
This was when she was presented to our outpatient clinic.
Results
To confirm peanut allergy and to determine the allergen
threshold dose, we performed open peanut challenge, dur-
ing which she developed anaphylaxis that required
epinephrine at a dose of 1.5g of peanut, corresponding to
one peanut. Because of the severity of the reaction and the
repeated incidents despite elimination diet, we decided for
a treatment with omalizumab, at a dose of 300mg every
4 weeks for 1 year, which was tolerated well by the patient.
Four weeks after the last dose we repeated the open
peanut challenge. The girl tolerated all doses with a cumu-
lative dose of 5g, corresponding to 3 peanuts, without any
symptoms. Total- and peanut-specific IgE levels remained
unchanged, whereas titrated skin prick test reactivity
slightly decreased. As a bystander effect, the girl’s cat- and
grass pollen allergy resolved completely.
Conclusion
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